## Ann Versporten

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4096177/publications.pdf

Version: 2024-02-01

186265 168389 2,976 68 28 53 h-index citations g-index papers 73 73 73 3712 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Point Prevalence Surveys of Antimicrobial Prescribing in a Non-Acute Care Hospital in Saitama Prefecture, Japan. Canadian Journal of Infectious Diseases and Medical Microbiology, 2022, 2022, 1-7.	1.9	3
2	Antimicrobial Prescribing Patterns in Patients with COVID-19 in Russian Multi-Field Hospitals in 2021: Results of the Global-PPS Project. Tropical Medicine and Infectious Disease, 2022, 7, 75.	2.3	7
3	Patterns of antimicrobial use in a specialized surgical hospital in Southeast Nigeria: Need for a standardized protocol of antimicrobial use in the tropics. Nigerian Journal of Medicine: Journal of the National Association of Resident Doctors of Nigeria, 2021, 30, 187.	0.1	1
4	Hospital antibiotic prescribing patterns in adult patients according to the WHO Access, Watch and Reserve classification (AWaRe): results from a worldwide point prevalence survey in 69 countries. Journal of Antimicrobial Chemotherapy, 2021, 76, 1614-1624.	3.0	60
5	Consumption of antibiotics in the community, European Union/European Economic Area, 1997–2017: data collection, management and analysis. Journal of Antimicrobial Chemotherapy, 2021, 76, ii2-ii6.	3.0	14
6	Consumption of antibiotics in the community, European Union/European Economic Area, 1997–2017. Journal of Antimicrobial Chemotherapy, 2021, 76, ii7-ii13.	3.0	40
7	Analysing the trend over time of antibiotic consumption in the community: a tutorial on the detection of common change-points. Journal of Antimicrobial Chemotherapy, 2021, 76, ii79-ii85.	3.0	10
8	Consumption of macrolides, lincosamides and streptogramins in the community, European Union/European Economic Area, 1997–2017. Journal of Antimicrobial Chemotherapy, 2021, 76, ii30-ii36.	3.0	16
9	Change-points in antibiotic consumption in the community, European Union/European Economic Area, 1997倓2017. Journal of Antimicrobial Chemotherapy, 2021, 76, ii68-ii78.	3.0	12
10	Consumption of tetracyclines, sulphonamides and trimethoprim, and other antibacterials in the community, European Union/European Economic Area, 1997–2017. Journal of Antimicrobial Chemotherapy, 2021, 76, ii45-ii59.	3.0	17
11	Quality appraisal of antibiotic consumption in the community, European Union/European Economic Area, 2009 and 2017. Journal of Antimicrobial Chemotherapy, 2021, 76, ii60-ii67.	3.0	15
12	Consumption of cephalosporins in the community, European Union/European Economic Area, 1997–2017. Journal of Antimicrobial Chemotherapy, 2021, 76, ii22-ii29.	3.0	14
13	Consumption of quinolones in the community, European Union/European Economic Area, 1997–2017. Journal of Antimicrobial Chemotherapy, 2021, 76, ii37-ii44.	3.0	34
14	Consumption of penicillins in the community, European Union/European Economic Area, 1997–2017. Journal of Antimicrobial Chemotherapy, 2021, 76, ii14-ii21.	3.0	17
15	Assessing the impact of the Global Point Prevalence Survey of Antimicrobial Consumption and Resistance (Global-PPS) on hospital antimicrobial stewardship programmes: results of a worldwide survey. Antimicrobial Resistance and Infection Control, 2021, 10, 138.	4.1	19
16	Antibiotic Prescribing Patterns in Ghana, Uganda, Zambia and Tanzania Hospitals: Results from the Global Point Prevalence Survey (G-PPS) on Antimicrobial Use and Stewardship Interventions Implemented. Antibiotics, 2021, 10, 1122.	3.7	36
17	Implementation of a multidisciplinary antimicrobial stewardship programme in a Philippine tertiary care hospital: an evaluation by repeated point prevalence surveys. Journal of Global Antimicrobial Resistance, 2021, 26, 157-165.	2.2	5
18	The 2018 Global Point Prevalence Survey of antimicrobial consumption and resistance in 47 Canadian hospitals: a cross-sectional survey. CMAJ Open, 2021, 9, E1242-E1251.	2.4	8

#	Article	IF	Citations
19	Antimicrobial Consumption and Resistance in a Tertiary Care Hospital in Jordan: Results of an Internet-Based Global Point Prevalence Survey. Antibiotics, 2020, 9, 598.	3.7	12
20	Evidence of Dose Variability and Dosing Below the FDA and EMA Recommendations for Intravenous Colistin (Polymyxin E) Use in Children and Neonates. Pediatric Infectious Disease Journal, 2020, 39, 1032-1034.	2.0	4
21	The 2017 global point prevalence survey of antimicrobial consumption and resistance in Canadian hospitals. Antimicrobial Resistance and Infection Control, 2020, 9, 104.	4.1	12
22	Point Prevalence Surveys and Customized Interventions Are Good Strategies to Improve Antimicrobial Use: The Brazilian Experience. Infection Control and Hospital Epidemiology, 2020, 41, s523-s523.	1.8	0
23	Longitudinal Point Prevalence Survey of Antimicrobial Consumption in Russian Hospitals: Results of the Global-PPS Project. Antibiotics, 2020, 9, 446.	3.7	9
24	Point prevalence surveys of antimicrobial use: a systematic review and the implications. Expert Review of Anti-Infective Therapy, 2020, 18, 897-910.	4.4	47
25	Point prevalence survey of antimicrobial use and healthcare-associated infections in Belgian acute care hospitals: results of the Global-PPS and ECDC-PPS 2017. Antimicrobial Resistance and Infection Control, 2020, 9, 13.	4.1	30
26	Use of the WHO Access, Watch, and Reserve classification to define patterns of hospital antibiotic use (AWaRe): an analysis of paediatric survey data from 56 countries. The Lancet Global Health, 2019, 7, e861-e871.	6.3	213
27	Point prevalence survey of antimicrobial prescription in a tertiary hospital in South East Nigeria: A call for improved antibiotic stewardship. Journal of Global Antimicrobial Resistance, 2019, 17, 291-295.	2.2	33
28	A multicenter point prevalence survey of antibiotic use in Punjab, Pakistan: findings and implications. Expert Review of Anti-Infective Therapy, 2019, 17, 285-293.	4.4	77
29	2018. The Global Point Prevalence Survey of Antimicrobial Consumption and Resistance: Quantity and Quality of Antimicrobial Prescribing for Inpatients with Pneumonia in the Philippines in 2018. Open Forum Infectious Diseases, 2019, 6, S677-S677.	0.9	O
30	Global Divergence From World Health Organization Treatment Guidelines for Neonatal and Pediatric Sepsis. Pediatric Infectious Disease Journal, 2019, 38, 1104-1106.	2.0	22
31	Antibiotic utilisation in adult and children patients in Kosovo hospitals. European Journal of Hospital Pharmacy, 2019, 26, 146-151.	1.1	5
32	High Rates of Prescribing Antimicrobials for Prophylaxis in Children and Neonates: Results From the Antibiotic Resistance and Prescribing in European Children Point Prevalence Survey. Journal of the Pediatric Infectious Diseases Society, 2019, 8, 143-151.	1.3	33
33	Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey. The Lancet Global Health, 2018, 6, e619-e629.	6.3	392
34	Comparative point prevalence survey of antimicrobial consumption between a hospital in Northern Ireland and a hospital in Jordan. BMC Health Services Research, 2018, 18, 849.	2.2	26
35	Using risk adjustment to improve the interpretation of global inpatient pediatric antibiotic prescribing. PLoS ONE, 2018, 13, e0199878.	2.5	5
36	Metrics for quantifying antibiotic use in the hospital setting: results from a systematic review and international multidisciplinary consensus procedure. Journal of Antimicrobial Chemotherapy, 2018, 73, vi50-vi58.	3.0	89

#	Article	IF	Citations
37	Variation in antibiotic use among and within different settings: a systematic review. Journal of Antimicrobial Chemotherapy, 2018, 73, vi17-vi29.	3.0	45
38	Quality indicators for responsible antibiotic use in the inpatient setting: a systematic review followed by an international multidisciplinary consensus procedure. Journal of Antimicrobial Chemotherapy, 2018, 73, vi30-vi39.	3.0	43
39	Quality indicators assessing antibiotic use in the outpatient setting: a systematic review followed by an international multidisciplinary consensus procedure. Journal of Antimicrobial Chemotherapy, 2018, 73, vi40-vi49.	3.0	61
40	Metrics to assess the quantity of antibiotic use in the outpatient setting: a systematic review followed by an international multidisciplinary consensus procedure. Journal of Antimicrobial Chemotherapy, 2018, 73, vi59-vi66.	3.0	30
41	Is there any difference in quality of prescribing between antibacterials and antifungals? Results from the first global point prevalence study (Global PPS) of antimicrobial consumption and resistance from 53 countries. Journal of Antimicrobial Chemotherapy, 2017, 72, 2906-2909.	3.0	10
42	Antibiotic Prescriptions and Prophylaxis in Italian Children. Is It Time to Change? Data from the ARPEC Project. PLoS ONE, 2016, 11, e0154662.	2.5	52
43	Using a simple point-prevalence survey to define appropriate antibiotic prescribing in hospitalised children across the UK. BMJ Open, 2016, 6, e012675.	1.9	56
44	Human biomonitoring of heavy metals in the vicinity of non-ferrous metal plants in Ath, Belgium. Archives of Public Health, 2016, 74, 42.	2.4	10
45	The Worldwide Antibiotic Resistance and Prescribing in European Children (ARPEC) point prevalence survey: developing hospital-quality indicators of antibiotic prescribing for children. Journal of Antimicrobial Chemotherapy, 2016, 71, 1106-1117.	3.0	238
46	The Global Point Prevalence Survey of Antimicrobial Consumption and Resistance (Global-PPS): A Worldwide Antimicrobial Web-Based Point Prevalence Survey. Open Forum Infectious Diseases, 2015, 2, .	0.9	6
47	Antibiotic Exposure and Other Risk Factors for Antimicrobial Resistance in Nasal Commensal Staphylococcus aureus: An Ecological Study in 8 European Countries. PLoS ONE, 2015, 10, e0135094.	2.5	39
48	Does exposure type impact differentially over time on the development of mental health disturbances after a technological disaster? Archives of Public Health, 2015, 73, 20.	2.4	1
49	A point prevalence surveillance study from pediatric and neonatal specialty hospitals in India. Journal of Pediatric Infectious Diseases, 2015, 09, 151-155.	0.2	2
50	Degree of exposure and peritraumatic dissociation as determinants of PTSD symptoms in the aftermath of the Ghislenghien gas explosion. Archives of Public Health, 2015, 73, 21.	2.4	10
51	Systemic antimycotic and antifungal use in eastern Europe: a cross-national database study in coordination with the WHO Regional Office for Europe. Journal of Antimicrobial Chemotherapy, 2015, 70, 2173-2175.	3.0	3
52	Antibiotic use in eastern Europe: a cross-national database study in coordination with the WHO Regional Office for Europe. Lancet Infectious Diseases, The, 2014, 14, 381-387.	9.1	225
53	Children Following the Ghislenghien Gas Explosion: PTSD Predictors and Risk Factors. Journal of Child and Adolescent Trauma, 2014, 7, 51-62.	1.9	0
54	Outpatient systemic antimycotic and antifungal use in Europe: New outcome measure provides new insight. International Journal of Antimicrobial Agents, 2013, 42, 466-470.	2.5	9

#	Article	IF	CITATIONS
55	Spatially explicit prioritization of human antibiotics and antineoplastics in Europe. Environment International, 2013, 51, 13-26.	10.0	49
56	Adaptive change-point mixed models applied to data on outpatient tetracycline use in Europe. Statistical Modelling, 2013, 13, 253-274.	1.1	5
57	The Antibiotic Resistance and Prescribing in European Children Project. Pediatric Infectious Disease Journal, 2013, 32, e242-e253.	2.0	143
58	European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe (1997–2009). Journal of Antimicrobial Chemotherapy, 2011, 66, vi3-vi12.	3.0	173
59	European Surveillance of Antimicrobial Consumption (ESAC): quality appraisal of antibiotic use in Europe. Journal of Antimicrobial Chemotherapy, 2011, 66, vi71-vi77.	3.0	95
60	Human biomonitoring on heavy metals in Ath: methodological aspects. Archives of Public Health, 2011, 69, 10.	2.4	10
61	European Surveillance of Antimicrobial Consumption (ESAC): systemic antiviral use in Europe. Journal of Antimicrobial Chemotherapy, 2011, 66, 1897-1905.	3.0	94
62	European Surveillance of Antimicrobial Consumption (ESAC): outpatient macrolide, lincosamide and streptogramin (MLS) use in Europe (1997–2009). Journal of Antimicrobial Chemotherapy, 2011, 66, vi37-vi45.	3.0	32
63	European Surveillance of Antimicrobial Consumption (ESAC): outpatient penicillin use in Europe (1997-2009). Journal of Antimicrobial Chemotherapy, 2011, 66, vi13-vi23.	3.0	27
64	European Surveillance of Antimicrobial Consumption (ESAC): outpatient cephalosporin use in Europe (1997-2009). Journal of Antimicrobial Chemotherapy, 2011, 66, vi25-vi35.	3.0	34
65	European Surveillance of Antimicrobial Consumption (ESAC): outpatient quinolone use in Europe (1997–2009). Journal of Antimicrobial Chemotherapy, 2011, 66, vi47-vi56.	3.0	81
66	European Surveillance of Antimicrobial Consumption (ESAC): outpatient use of tetracyclines, sulphonamides and trimethoprim, and other antibacterials in Europe (1997–2009). Journal of Antimicrobial Chemotherapy, 2011, 66, vi57-vi70.	3.0	31
67	Application of mixed-effects models to study the country-specific outpatient antibiotic use in Europe: a tutorial on longitudinal data analysis. Journal of Antimicrobial Chemotherapy, 2011, 66, vi79-vi87.	3.0	24
68	Global Point Prevalence Survey in Five Teaching Hospitals in Baghdad, Iraq. Mediterranean Journal of Infection, Microbes and Antimicrobials, 0, , .	0.2	0